Vidac Pharma Holding PLC
Company Profile
Business description
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company’s research targets the modification of the tumor microenvironment to inhibit cancer cell growth by selectively affecting metabolic checkpoints in cancer cells without harming normal tissue. Its drug pipeline includes candidates such as VDA-1102 ointment, VDA-1102 IV, and VDA-1275, which are designed to treat conditions like Actinic Keratosis and Cutaneous T-cell Lymphoma. Vidac Pharma operates internationally with headquarters in London and aims to treat cancer through novel chemical entities.
Contact
20-22 Wenlock Road
LondonN1 7GU
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |